Screener
Kiniksa Pharmaceuticals International, plc KNSA Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-087545
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Class B ordinary shares, nominal value of $0.000273235 per share; 895,158 shares and 1,795,158 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 1 | 1 |
| Class A1 ordinary shares, nominal value of $0.000273235 per share; 12,781,964 shares issued and outstanding as of June 30, 2026 and December 31, 2025 | 4 | 4 |
| Class B1 ordinary shares, $0.000273235 nominal value; 16,057,618 shares issued and outstanding as of June 30, 2026 and December 31, 2025 | 4 | 4 |
| Additional paid-in capital | 1,069,622 | 1,029,748 |
| Accumulated other comprehensive loss | (1,380) | (25) |
| Accumulated deficit | (414,114) | (462,138) |
| Total shareholders’ equity | 654,149 | 567,606 |
| Total liabilities and shareholders’ equity | $896,110 | $763,633 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kiniksa Pharmaceuticals International, plc's retained earnings?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported retained earnings of -$414.11M in Q2 2026.
- How has Kiniksa Pharmaceuticals International, plc's retained earnings changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's retained earnings increased by 16.3% year-over-year, from -$494.77M to -$414.11M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's retained earnings?
- Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's retained earnings has grown at a -2.2% compound annual growth rate (CAGR), from -$517.47M to -$462.14M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Kiniksa Pharmaceuticals International, plc's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude